Rhumbline Advisers Abeona Therapeutics Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 58 shares of ABEO stock, worth $245. This represents 0.0% of its overall portfolio holdings.
Number of Shares
58
Previous 58
-0.0%
Holding current value
$245
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ABEO
# of Institutions
65Shares Held
14.4MCall Options Held
715KPut Options Held
58K-
Adage Capital Partners Gp, L.L.C. Boston, MA3.25MShares$13.8 Million0.05% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.31MShares$9.8 Million1.08% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.99MShares$8.42 Million0.01% of portfolio
-
Western Standard LLC Los Angeles, CA1.36MShares$5.77 Million4.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$4.67 Million0.0% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $25.2M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...